Compare AJG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AJG | EW |
|---|---|---|
| Founded | 1927 | 1958 |
| Country | United States | United States |
| Employees | 706000 | N/A |
| Industry | Specialty Insurers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.4B | 49.5B |
| IPO Year | 1995 | 1999 |
| Metric | AJG | EW |
|---|---|---|
| Price | $222.02 | $86.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $274.60 | $96.37 |
| AVG Volume (30 Days) | 1.6M | ★ 4.7M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.16 | 0.66 |
| Revenue | ★ $6,159,600,000.00 | $6,067,600,000.00 |
| Revenue This Year | $30.53 | $13.39 |
| Revenue Next Year | $9.13 | $9.81 |
| P/E Ratio | ★ $69.66 | $130.27 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $190.75 | $72.30 |
| 52 Week High | $323.25 | $89.48 |
| Indicator | AJG | EW |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 54.57 |
| Support Level | $203.75 | $81.73 |
| Resistance Level | $228.55 | $87.22 |
| Average True Range (ATR) | 5.43 | 2.39 |
| MACD | 2.39 | -0.09 |
| Stochastic Oscillator | 87.05 | 47.80 |
Founded in 1927 as a one-person agency, Gallagher's primary business is insurance brokerage, with a focus on serving middle-market companies. The company's risk management segment provides third-party claims adjustment to companies that choose to self-insure. Gallagher has about 72,000 employees and generates about a third of its revenue internationally, primarily in Australia, Canada, New Zealand, and the UK.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.